

# OncoSET: Future of Precision Medicine for Cancer Treatment



## What is the OncoSET Program?

Designed to provide personalized evaluations and customized treatment plans for patients with cancer, the Lurie Cancer Center OncoSET (Sequence, Evaluate, Treat) Program takes a comprehensive approach to precision medicine.

The OncoSET Program combines genomic sequencing and molecular analysis with standard pathology to identify precisely tailored treatments and clinical trials for patients whose cancers are resistant to traditional therapies. Patients have access to Lurie Cancer Center OncoSET in three outpatient clinical cancer center locations on Northwestern Medicine's Chicago campus.

## How is precision medicine being used to help cancer patients?

Precision medicine, also called personalized medicine, uses detailed information about the specific genetic and molecular makeup of a patient's tumor to increase the effectiveness, reduce the side effects of cancer treatment, and improve quality of life.

A primary goal of precision medicine in cancer treatment is to design and implement treatment plans based on genetic alterations instead of a tumor's location.

## What sets OncoSET apart from other precision medicine programs?

An essential component of the program, the **OncoSET Molecular Tumor Board** includes world class-physicians and scientists, including:

- Medical oncologist
- Surgical oncologist
- Radiation oncologists
- Molecular pathologists
- Radiologists
- Pharmacogenomics specialists (*who examine how genes impact a person's response to drugs*)

The Molecular Tumor Board creates a comprehensive summary of test results for each patient, including the evaluation and recommendations for treatment. Genetic counseling is available to help patients assess their risk factors and make informed decisions to protect their health. Patients have access to individually tailored therapies and clinical trials.

## Who should consider OncoSET?

The OncoSET Program's physicians are currently treating patients with advanced or refractory cancers for whom results can help guide treatment choices. Patients with tumors from **any type of cancer** that are not responsive to standard forms of treatment are potential candidates for OncoSET.

To learn more contact the OncoSET program coordinator, Jeannine Donahue, at [OncoSET@northwestern.edu](mailto:OncoSET@northwestern.edu)



**Lurie Cancer Center OncoSET Program is led by**

Massimo Cristofanilli, MD  
Association Director for Translational Research and  
Precision Medicine

**To refer a patient or request a consultation contact**

Jeannine Donahue  
OncoSET Program Coordinator  
**312.472.6392 or 844.662.6738 (toll-free)**  
Email: [oncoSET@northwestern.edu](mailto:oncoSET@northwestern.edu)